A Randomized, Placebo-controlled, Double-blinded, Crossover Trial of Pioglitazone for Severe Asthma

The PPAR-γ agonist, pioglitazone, was associated with significant side effects and did not improve the primary outcome measure of the Juniper Asthma Quality of Life Questionnaire (AQLQ) score in severe asthmatics. We conclude that no further studies should be performed with pioglitazone for severe a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Allergy Clin Immunol
Egile Nagusiak: Kaler, Maryann, Barochia, Amisha V., Weir, Nargues A., Cuento, Rosemarie A., Stylianou, Mario, Roth, Mark J., Filie, Armando C., Vaughey, Ellen C., Nathan, Steven D., Levine, Stewart J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5723231/
https://ncbi.nlm.nih.gov/pubmed/28625806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2017.05.033
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak